Understanding heart function and structure in patients with primary aldosteronism
Official title: (Administrative Supplement) Cardiac Perfusion, Structure, and Function across the Primary Aldosteronism Spectrum
Funded at Brigham and Women's Hospital · NIH-11200687 · Data updated 2026-11-12
This study is looking at how primary aldosteronism impacts heart health in people with heart failure that still pumps well, and it will explore how a medication called spironolactone might help improve their heart function and structure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 15, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $75,460 |
| NIH project number | 3K23HL159279-04S1 |
| Project ID | NIH-11200687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with primary aldosteronism, particularly those experiencing heart failure with preserved ejection fraction.
✕Less likely to help
Patients without primary aldosteronism or those not experiencing heart-related issues may not benefit from this research.
What this research studies
This research investigates how primary aldosteronism affects heart function and structure, particularly in patients with heart failure with preserved ejection fraction (HFpEF). It aims to explore the mechanisms by which mineralocorticoid receptor antagonists, like spironolactone, can improve heart health in these patients. The study will involve assessing cardiac perfusion, structure, and function through advanced imaging techniques and clinical evaluations. By understanding these relationships, the research seeks to identify better treatment strategies for those affected by this condition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with heart failure and primary aldosteronism, potentially reducing cardiovascular risks.
How similar studies have gone: Previous research has shown promising results with mineralocorticoid receptor antagonists in similar patient populations, indicating potential for success in this area.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Brown, Jenifer Michelle — Brigham and Women's Hospital
- Study coordinator: Brown, Jenifer Michelle
Related research
Other NIH-funded projects on the same topics.
-
Unrecognized Primary Aldosteronism and Kidney Disease in Diabetes
A study at Brigham and Women’s Hospital will explore whether unrecognized primary aldosteronism contributes to kidney disease and heart risk in people with diabetes.
-
Understanding why primary aldosteronism screening is missing or delayed
A Mayo Clinic-led study aims to understand why many people at risk for primary aldosteronism are not being screened early enough and what can be done to fix it.
-
Investigating how unrecognized primary aldosteronism contributes to kidney disease in diabetes
This study is looking at how a condition called primary aldosteronism might affect kidney health in people with diabetes, and it aims to find those who may not know they have it so they can get the right care to protect their kidneys.
-
Investigating the reasons for low and delayed screening of primary Aldosteronism
This study is looking into why not enough people at risk for primary aldosteronism get tested for it, even though it can cause serious health problems, and it aims to find ways to make screening easier and more accessible for everyone.
-
Investigating the causes and effects of primary aldosteronism subtypes
This study is looking at primary aldosteronism, a condition that causes high blood pressure, to find better ways to diagnose it using blood tests and tissue samples, so patients can get the right treatment without needing invasive procedures.
-
Investigating heart function and blood flow in patients with primary aldosteronism.
This study is looking at how a condition called primary aldosteronism impacts heart health in people with heart failure and how a specific type of medication might help improve their heart function by reducing inflammation, so we can find out who might benefit the most from this treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.